Background Venous thromboembolism is the leading cause of death in cancer patients,
second only to tumor progression. The Khorana score is recommended by clinical …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Aims This meta-analysis was conducted to evaluate the validity of the Caprini venous
thromboembolism (VTE) risk assessment scale in predicting the risk of VTE in inpatients with …

OBJECTIVES This study aimed to evaluate the optimal risk assessment model (RAM) to
stratify the risk of venous thromboembolism (VTE) in hospitalized patients with cancer. We …

Background: Guidelines suggest the use of the Khorana score to select patients with solid
cancer receiving chemotherapy for thromboprophylaxis to prevent venous thromboembolism …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Cancer patients with venous thromboembolism (VTE) are prone to poor prognoses. Thus,
we aimed to develop a nomogram to predict the risk of VTE in these patients. We …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

Venous thromboembolism (VTE) is the second most common cause of cancer-related
deaths globally. The Khorana score, a VTE prediction model, is calculated using the site of …